Maxim Group analyst Jason McCarthy maintained a Buy rating on Rezolute (RZLT – Research Report) yesterday and set a price target of $15.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Rezolute’s financial and clinical developments. The company recently reported a net loss but maintains a strong cash position, bolstered by a significant equity financing that extends its financial runway into mid-2027. This financial stability supports the ongoing development of their key drug candidate, ersodetug, which is in a pivotal Phase 3 trial for congenital hyperinsulinism (CHI).
Furthermore, the Phase 3 sunRIZE study for ersodetug is progressing well, with enrollment expected to complete soon and top-line data anticipated by December 2025. The trial’s continuation without the need for an increased sample size, as recommended by the independent Data Monitoring Committee, underscores the drug’s potential efficacy. Additionally, the planned Phase 3 study for tumor hyperinsulinism, which could represent a market opportunity twice the size of CHI, further strengthens the investment case for Rezolute.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RZLT in relation to earlier this year.